A randomized comparison of tamoxifen with surgical oophorectomy in premenopausal patients with advanced breast cancer.
Buchanan, R B Blamey, R W Durrant, K R Howell, Anthony Paterson, A G Preece, P E Smith, David B Williams, C J Wilson, R G
Buchanan, R B
Blamey, R W
Durrant, K R
Howell, Anthony
Paterson, A G
Preece, P E
Smith, David B
Williams, C J
Wilson, R G
Citations
Altmetric:
Abstract
We randomized 122 premenopausal women to receive tamoxifen or to undergo a surgical oophorectomy. Of 54 evaluable women treated with tamoxifen, 24% had an objective response, as compared with 21% of 53 women having an oophorectomy. The median duration of response for tamoxifen (20 months) was longer than that for surgical oophorectomy (7 months), but this did not achieve statistical significance (P = .056). Overall median survival was 15 months for 58 patients receiving tamoxifen and 25 months for 53 patients undergoing oophorectomy (P = .18). Toxicity was greater in those undergoing oophorectomy, though both treatments were well tolerated. In those premenopausal women for whom hormonal therapy is indicated, tamoxifen is a suitable alternative to surgical oophorectomy.
Affiliation
Description
Date
1986-09
Publisher
Collections
Keywords
Breast Cancer
Cancer Metastasis
Oestrogen Receptors
Cancer Metastasis
Oestrogen Receptors
Type
Article
Citation
A randomized comparison of tamoxifen with surgical oophorectomy in premenopausal patients with advanced breast cancer. 1986, 4 (9):1326-30 J. Clin. Oncol.